Chong Kun Dang exclusively sells female sexual dysfunction treatment for the first time in Korea

Chong Kun Dang(CEO Young-joo Kim) established an exclusive sales agreement of a female sexual dysfunction treatment with S1 Biopharma, a U.S. company, at the Chong Kun Dang headquarters at Chungjeongno, Seoul, for the first time in Korea on the 4^th.

The drug is currently under a phase 2 clinical trial in the U.S. by S1 Biopharma. Chong Kun Dang is planning to commercialize the product in 2019 ...